{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:22:37Z","timestamp":1747977757738},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TaiShang Resources International Group, Taiwan","award":["Golden Dream Project"],"award-info":[{"award-number":["Golden Dream Project"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0161811","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T18:01:42Z","timestamp":1475776902000},"page":"e0161811","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review"],"prefix":"10.1371","volume":"11","author":[{"given":"Ya-Ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Jeng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiehfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mikhaylichenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsien-Tsai","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsin Elsa","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11864-013-0232-x","article-title":"Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?","volume":"14","author":"MA Lunning","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2008.07.010","article-title":"Peripheral T-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"JM Vose","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref3","first-page":"3909","article-title":"The Non- Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","article-title":"The changing landscape of peripheral T-cell lymphoma in the era of novel therapies","volume":"51","author":"L Karlin","year":"2014","journal-title":"Semin Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"B Coiffier","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"J Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrclinonc.2011.51","article-title":"Hematology: relapsed and refractory PTCL\u2013into the therapeutic abyss","volume":"8","author":"F Foss","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"AN Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after f\u0131rst relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"V Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/10428194.2010.542596","article-title":"Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis","volume":"52","author":"D Morgensztern","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminhematol.2013.11.006","article-title":"Chemotherapeutic advancements in peripheral T-cell lymphoma","volume":"51","author":"NM Reddy","year":"2014","journal-title":"Semin Hematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.14694\/EdBook_AM.2015.35.e468","article-title":"Novel treatments for T-cell lymphoma","volume":"35","author":"CY Cheah","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"OA O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"B Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"B Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"F Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"ref17","unstructured":"National Comprehensive Cancer Network: NCCN clinical practice guideline on oncology: Non-Hodgkin\u2019s lymphomas, Version 5, 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf.Accessed\" xlink:type=\"simple\">http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf.Accessed<\/ext-link> 10 Dec 2014."},{"key":"ref18","unstructured":"Sterne JAC, Higgins JPT, Reeves BC on behalf of the development group for ACROBATNRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBATNRSI), Version 1.0.0, 24 September 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.riskofbias.info\" xlink:type=\"simple\">http:\/\/www.riskofbias.info<\/ext-link>. Accessed 30 Jun 2015."},{"key":"ref19","unstructured":"Moga C, Guo B, Schopflocher D, Harstall C. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton AB: Institute of Health Economics, 2012."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"SM Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"G Enblad","year":"2004","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, openlabel, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"G Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"PL Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"PL Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"F Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"F d'Amore","year":"2010","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/1042819022386806","article-title":"Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma","volume":"43","author":"CL Huang","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","article-title":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity","volume":"30","author":"SJ Kim","year":"2012","journal-title":"Invest New Drugs"},{"issue":"suppl 1","key":"ref29","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"14","author":"AD Zelenetz","year":"2003","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A Revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"NL Harris","year":"1994","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"WS Velasquez","year":"1998","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"WS Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3109\/10428194.2013.779688","article-title":"Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy","volume":"54","author":"E Koch","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-04-565267","article-title":"Time has come for immunotherapy in PTCL","volume":"123","author":"E Bachy","year":"2014","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3109\/10428194.2011.645818","article-title":"Long-term survival in patients with peripheral T-cell non- Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant","volume":"53","author":"JD Goldberg","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1200\/JCO.2010.28.5635","article-title":"Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression","volume":"28","author":"D Rades","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2407-11-335","article-title":"Matched-pair analysis of patients with female and male breast cancer: a comparative analysis","volume":"11","author":"R Foerster","year":"2011","journal-title":"BMC Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-2501-2-3","article-title":"Big data analytics in healthcare: promise and potential","volume":"2","author":"W Raghupathi","year":"2014","journal-title":"Health Inf Sci Syst"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"British Medical Journal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0161811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T13:01:32Z","timestamp":1601125292000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0161811"}},"subtitle":[],"editor":[{"given":"Jian-Xin","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0161811","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}